Antihistamines in pediatric practice: what we need to know?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, antihistamines are the one of most commonly used drugs in children. They are used to treat symptoms that are associated with the histamine release, primarily allergic diseases - atopic dermatitis, allergic rhinitis, bronchial asthma, allergic conjunctivitis, urticaria, systemic anaphylactic reactions, and histamine plays one of the key roles in their development. There are first and second generation (old and new) antihistamines. Their pharmacological effects and therapeutic indications are similar, but second generation antihistamines have significantly fewer side effects, since they are characterized by a selective effect on H1-histamine receptors. Despite the fact that antihistamines have been present on the pharmaceutical market for many years, there are still many side effects associated with their unfavorable safety profile, especially in pediatric practice. Antihistamines are predominantly over-the-counter drugs and are often misused, which is undesirable, especially for children under 2 years of age, since most drugs have no safety data for this age group and many antihistamines are not recommended. The article provides information on histamine receptors and Hi receptor agonists, as well as information on the use of antihistamines in children.

Full Text

Restricted Access

About the authors

Vilya A. Bulgakova

National Medical Research Center for Children's Health

Email: irvilbulgak@mail.iu
Dr. Sci. (Med.), Chief Researcher at the Laboratory of Research Forecasting and Planning 2, build. 1, Lomonosovsky Prospect, Moscow 119991, Russian Federation

E. N Kareva

Pirogov Medical University; Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia; Moscow, Russia

L. R Selimzyanova

Sechenov First Moscow State Medical University (Sechenov University); Central Clinical Hospital of the Russian Academy of Sciences

Moscow, Russia; Moscow, Russia

T. E Privalova

Pirogov Medical University; Central Clinical Hospital of the Russian Academy of Sciences

Moscow, Russia; Moscow, Russia

References

  1. Rosenbaum D.M., Rasmussen S.G., Kobilka B.K The structure and function of G-protein-coupled receptors. Nature. 2009;459(7245):356-63. doi: 10.1038/nature08144.
  2. Hill S.J., Ganellin C.R., Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev. 1997;49(3):253-78.
  3. Hofstra C.L., Desai P.J., Thurmond R.L., Fung-Leung W.P. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther. 2003;305(3):1212-21. doi: 10.1124/jpet.102.046581.
  4. Neumann D., Schneider E.H., Seifert R. Analysis of histamine receptor knockout mice in models of inflammation. J Pharmacol Exp Then 2014;348(1):2-11. doi: 10.1124/jpet.113.204214.
  5. Nent E., Frommholz D., Gajda M., et al. Histamine 4 receptor plays an important role in auto-antibody-induced arthritis. Int Immunol. 2013;25(7):437-43. doi: 10.1093/intimm/dxt008.
  6. Bakker R.A, Schoonus S.B., Smit M.J., et al. Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol. 2001;60(5):1133-42. doi: 10.1124/mol.60.5.1133.
  7. Tatarkiewicz J., Rzodkiewicz P., Zochowska M., et al. New antihistamines - perspectives in the treatment of some allergic and inflammatory disorders. Arch Med Sci. 2019;15(2):537-53. doi: 10.5114/aoms.2017.68534.
  8. Dunford P.J., O'Donnell N., Riley J.P., et al. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol. 2006; 176(11):7062-70. doi: 10.4049/jimmunol.176.11.7062.
  9. Morgan R.K., McAllister B., Cross L., et al. Histamine 4 receptor activation induces recruitment of FoxP3+ T cells and inhibits allergic asthma in a murine model. J Immunol. 2007;178(12):8081-89. doi: 10.4049/jimmunol.178.12.8081.
  10. Shiraishi Y., Jia Y., Domenico J., et al. Sequential engagement of FcsRI on Mast Cells and Basophil Histamine H(4) Receptor and FcεRI in Allergic Rhinitis. J Immunol. 2013;190(2):539-48. doi: 10.4049/jimmunol.1202049.
  11. Salcedo C, Pontes C., Merlos M. Is the H4 receptor a new drug target for allergies and asthma? Front Biosci (Elite Ed). 2013;5:178-87. Published 2013 Jan 1. doi: 10.2741/e606.
  12. Фомина Д.С., Дробик О.С., Горячкина Л.А. Антигистаминные препараты: современные критерии выбора. Consilium medicum. 2012;14(11):11-6.
  13. Hide M., Hiragun T.; Japanese Dermatological Association. Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries. Allergol Int. 2012;61(4):517-27. doi: 10.2332/allergolint.12-RAI-0497.
  14. Bruysters M., Jongejan A., Gillard M., et al. Pharmacological differences between human and guinea pig histamine H1 receptors: Asn84 (2.61) as key residue within an additional binding pocket in the H1-receptor. Mol Pharmacol. 2005;67(4):1045-52. doi: 10.1124/mol.104.008847.
  15. Гущин И.С. Обоснование многообразия противоаллергического действия обратных агонистов H1-рецепторов. Пульмонология. 2008;6:84-9.
  16. Клиническая аллергология детского возраста с неотложными состояниями. Под ред. И.И. Балаболкина, В.А. Булгаковой. М., 2011. 264 с.
  17. Hart L.A., Krishnan V.L., Adcock I.M., et al. Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1585-92. doi: 10.1164/ajrccm.158.5.9706116.
  18. Verster J.C., Volkerts E.R. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic [published correction appears in Ann Allergy Asthma Immunol. 2004 Jun;92(6):675] [published correction appears in Ann Allergy Asthma Immunol. 2005 Mar;94(3):409-10]. Ann Allergy Asthma Immunol. 2004;92(3):294-355. doi: 10.1016/S1081-1206(10)61566-9.
  19. Church M.K., Maurer M., Simons F.E., et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459-66. doi: 10.1111/j.1398-9995.2009.02325.x.
  20. Weiler J.M., Bloomfield J.R., Woodworth G.G., et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med. 2000;132(5):354-63. doi: 10.7326/0003-4819-132-5-200003070-00004.
  21. Motola D., Donati M., Biagi C., et al. Safety profile of H^-antihistamines in pediatrics: an analysis based on data from VigiBase. Pharmacoepidemiol Drug Saf. 2017;26(10):1164-71. doi: 10.1002/pds.4246.
  22. Walker S., Khan-Wasti S., Fletcher M., et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007;120(2):381-87. doi: 10.1016/j.jaci.2007.03.034.
  23. Roberts G., Xatzipsalti M., Borrego L.M., et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68(9):1102-16. doi: 10.1111/all.12235.
  24. Zuberbier T., Asero R., Bindslev-Jensen C., et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64(10):1417-26. doi: 10.1111/j.1398-9995.2009.02179.x.
  25. Pite H., Wedi B., Borrego L.M., et al. Management of childhood urticaria: current knowledge and practical recommendations. Acta Derm Venereol. 2013;93(5):500-8. doi: 10.2340/00015555-1573.
  26. Bachert C., Maspero J. Efficacy of second-generation antihistamines in patients with allergic rhinitis and comorbid asthma. J Asthma. 2011;48(9):965-73. doi: 10.3109/02770903.2 011.616616.
  27. Weber-Schoendorfer C., Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol. 2008;26(1):19-23.
  28. Gillard M., Christophe B., Wels B., et al. H1 antagonists: receptor affinity versus selectivity. Inflamm Res. 2003;52(Suppl 1):S49-S50. doi: 10.1007/s000110300050.
  29. Molimard M., Diquet B., Benedetti M.S. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004;18(4):399-411. doi: 10.1111/j.1472-8206.2004.00254.x.
  30. Devillier P., Roche N., Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. doi: 10.2165/00003088-200847040-00001.
  31. Thundiyil J.G., Kearney T.E., Olson K.R. Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. J Med Toxicol. 2007;3(1):15-9. doi: 10.1007/BF03161033.
  32. Naso C., Jenkins A.J., Younger D. 3rd. A study of drug detection in a postmortem pediatric population. J Forensic Sci. 2008;53(2):483-90. doi: 10.1111/j.1556-4029.2007.00646.x.
  33. Fitzsimons R., van der Poel L.A., Thornhill W., et al. Antihistamine use in children. Arch Dis Child Educ Pract Ed. 2015;100(3):122-131. doi: 10.1136/archdischild-2013-304446.
  34. Church M.K., Maurer M., Simons F.E., et al. Risk of first-generation H(1)-antihistamines: a GA(2) LEN position paper. Allergy. 2010;65(4):459-66. doi: 10.1111/j.1398-9995.2009.02325.x.
  35. Licari A., Ciprandi G., Marseglia A., et al. Current recommendations and emerging options for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2014;10(10):1337-47. doi: 10.1586/1744666X.2014.955476.
  36. Brozek J.L., Bousquet J., Agache I., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-58. doi: 10.1016/j.jaci.2017.03.050.
  37. Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-414. doi: 10.1111/all.13397.
  38. Намазова-Баранова Л.С., Баранов А.А., Кубанова А.А. и др. Атопический дерматит у детей: современные клинические рекомендации по диагностикеи терапии. Вопросы современной педиатрии. 2016;15(3):279-294. doi: 10.15690/vsp.v15i3.1566.
  39. Балаболкин И. И., Булгакова В. А., Елисеева Т. И. Атопический дерматит у детей. М.: МИА, 2018. 304 с.
  40. Muraro A., Roberts G., Worm M., et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69(8):1026-45. doi: 10.1111/all.12437.
  41. Yamauchi K., Ogasawara M. The Role of Histamine in the Pathophysiology of Asthma and the Clinical Efficacy of Antihistamines in Asthma Therapy. Int J Mol Sci. 2019;20(7):1733. doi: 10.3390/ijms200 71733.
  42. LicariA., Castagnoli R., Denicolô C.F., et al. The Nose and the Lung: United Airway Disease? Front Pediatr. 2017;5:44. doi: 10.3389/fped.2017.00044.
  43. Smith S.M., Schroeder K., Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2014;Nov 24;(11):CD001831.
  44. De Sutter A.I., Saraswat A., van Driel M.L. Antihistamines for the common cold. Cochrane Database Syst Rev. 2015 Nov 29;11:CD009345. doi: 10.1002/14651858.CD009345.pub2.
  45. Chang A.B., Peake J., McElrea M.S. Anti-histamines for prolonged non-specific cough in children. Cochrane Database Syst Rev. 2006;(3):CD005604. doi: 10.1002/14651858.CD005604.pub2.
  46. Naqvi A., Gerriets V Cetirizine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 27, 2020.
  47. Corsico A.G., Leonardi S., Licari A., et al. Focus on the cetirizine use in clinical practice: a reappraisal 30 years later. Multidiscip Respir Med. 2019;14:40. doi: 10.1186/s40248-019-0203-6.
  48. Gillman S., Gillard M., Benedetti M.S. The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistamines. Allergy Asthma Proc. 2009;30(4):366-76. doi: 10.2500/aap.2009.30.3226.
  49. Golightly L.K., Greos L.S. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs. 2005;65(3):341-84. doi: 10.2165/00003495-200565030-00004.
  50. dos Santos R.V., Magerl M., Mlynek A., Lima H.C. Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. Ann Allergy Asthma Immunol. 2009;102(6):495-99. doi: 10.1016/S1081-1206(10)60123-8.
  51. Инструкция по медицинскому применению препарата Зодак капли РУ ЛС-000433-180711, Зодак таблетки РУ П N 013867/01-150212.
  52. Зайцева С.В., Локшина Э.Э., Муртазаева О.А. и др. Современные возможности терапии поллиноза у детей. Русский медицинский журнал. 2012;6:314-319.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies